TIGIT antibody set

TIGIT Detection Set (Risk Free)

Cat. Num. AAA154704

• Reactivity: Human
• Applications: ELISA, Immunocytochemistry, Immunohistochemistry, Flow Cytometry, Functional Assay, Immunofluorescence
• Purity: Antibodies are supplied as protein A purified IgG2b
• Synonyms: TIGIT; Monoclonal Antibody Set; TIGIT Detection Set (Risk Free); TIGIT antibody set

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: IgG1, IgG2a, IgG2b
• Purity/Purification: Antibodies are supplied as protein A purified IgG2b
• Form/Format: Liquid. PBS containing 0.02% sodium azide.
• Concentration: Antibody 1mg/mL (varies by lot)

• Applicable Applications for TIGIT antibody set: ELISA (EIA), Immunocytochemistry (ICC), Immunohistochemistry (IHC)-Paraffin, Flow Cytometry (FC/FACS), Immunofluorescence (IF)
• Immunogen: TIGIT antibodies were raised against the extracellular domain of human TIGIT.
• Conjugation: Unconjugated
• Preparation and Storage: Antibodies can be stored at 4 degree C for three months and -20 degree C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Related Product Information for TIGIT antibody set

The T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a member of the PVR (poliovirus receptor) family of immunoglobin proteins. It is expressed on several classes of T cells including follicular B helper T cells (TFH). TIGIT has been shown to bind PVR with high affinity; this binding is thought to assist interactions between TFH and dendritic cells to regulate T cell dependent B cell responses (1). Similar to other immune checkpoint proteins such as PD-1, TIGIT is upregulated on exhausted T cells in chronic viral infections and cancer. Blockade of both TIGIT and PD-1 pathways leads to tumor rejection in mice suggesting that it may be of therapeutic use against cancer (2). Risk-Free antibodies are mouse monoclonal antibodies made to improve in vivo studies. Unlike antibodies developed using proteins made in yeast or bacteria, Risk-Free antibodies are developed with antigens expressed in mammalian cell lines, giving the most native post-translational modifications to the protein. Validated for flow cytometry and ELISA Rigorously tested for the following applications: Immunoblot Immunohistochemistry Immunocytochemistry Immunofluorescence Multiple antibodies per target allowing the user to choose the best antibody for their application Available individually or as a set Risk-Free means they are guaranteed to work for their approved applications

References

Stanietsky N, Simic H, Arapovic J, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA 2009; 106:17858-63.
Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014; 26:923-37.